Literature DB >> 2431857

Inosine pranobex. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

D M Campoli-Richards, E M Sorkin, R C Heel.   

Abstract

Inosine pranobex is a synthetic compound formed from the p-acetamido benzoate salt of N-N dimethylamino-2-propanol and inosine in a 3:1 molar ratio. It has been reported to exert antiviral and antitumour activities in vivo which are secondary to an immunomodulating effect, and early results suggest beneficial clinical effects in several diseases and infections including mucocutaneous Herpes simplex infections, subacute sclerosing panencephalitis, genital warts, influenza, zoster, and type B viral hepatitis, as well as in homosexual men with persistent generalised lymphadenopathy. However, many of the studies have been preliminary in nature and deficient in design or in the reporting of their results. One must therefore conclude that while inosine pranobex may prove to be a valuable and innovative therapy for a number of diseases and infections for which no satisfactory therapy exist, further long term well controlled studies in larger numbers of patients are required before definitive conclusions about the efficacy of inosine pranobex in these disorders will be possible.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2431857     DOI: 10.2165/00003495-198632050-00001

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  117 in total

1.  [Isoprinosine: evaluation of its virus inhibiting action in vivo and in vitro].

Authors:  H J Eggers; A Neufahrt; H Rolly
Journal:  Dtsch Med Wochenschr       Date:  1972-08-04       Impact factor: 0.628

2.  Effect of isoprinosine against influenza and some other viruses causing respiratory diseases.

Authors:  R L Muldoon; L Mezny; G G Jackson
Journal:  Antimicrob Agents Chemother       Date:  1972-09       Impact factor: 5.191

3.  [Effect of a treatment with methisoprinol on the frequency and duration of infectious respiratory and urinary episodes in the elderly].

Authors:  P L Meroni; R Palmieri; G Palmieri; M Froldi; C Zanussi
Journal:  Recenti Prog Med       Date:  1984-12

4.  Medical registers as historical controls: analysis of an open clinical trial of inosiplex in subacute sclerosing panencephalitis.

Authors:  F K Hoehler; N Mantel; E Gehan; E Kahana; M Alter
Journal:  Stat Med       Date:  1984 Jul-Sep       Impact factor: 2.373

5.  The immunomodulatory action of inosiplex in relation to its effects in experimental viral infections.

Authors:  H Ohnishi; H Kosuzume; H Inaba; M Ohkura; S Shimada; Y Suzuki
Journal:  Int J Immunopharmacol       Date:  1983

6.  An in vitro study on the effects of isoprinosine on immune responses in cancer patients.

Authors:  K Y Tsang; H H Fudenberg; J F Pan; M J Gnagy; C B Bristow
Journal:  Int J Immunopharmacol       Date:  1983

7.  Failure of oral inosiplex treatment of recurrent herpes simplex virus infections.

Authors:  K O Kalimo; I A Joronen; V K Havu
Journal:  Arch Dermatol       Date:  1983-06

8.  Immunologic studies in homosexual and hemophiliac subjects with persistent generalized lymphadenopathy: a comparative analysis.

Authors:  C B Daul; R D deShazo; W A Andes; G A Pankey
Journal:  J Allergy Clin Immunol       Date:  1986-02       Impact factor: 10.793

9.  Modulation of human T lymphocyte functions by isoprinosine.

Authors:  A Rey; D Cupissol; C Thierry; C Esteve; B Serrou
Journal:  Int J Immunopharmacol       Date:  1983

10.  Effect of isoprinosine on interleukin 1 and 2 production and on suppressor cell activity in pokeweed mitogen stimulated cultures of B and T cells.

Authors:  P Hersey; C Bindon; M Bradley; E Hasic
Journal:  Int J Immunopharmacol       Date:  1984
View more
  21 in total

Review 1.  Discovery of immunopotentiatory drugs: current and future strategies.

Authors:  J Rhodes
Journal:  Clin Exp Immunol       Date:  2002-12       Impact factor: 4.330

Review 2.  Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis.

Authors:  Kirk R Wilhelmus
Journal:  Cochrane Database Syst Rev       Date:  2015-01-09

Review 3.  Antiviral therapy in AIDS. Clinical pharmacological properties and therapeutic experience to date.

Authors:  E G Sandström; J C Kaplan
Journal:  Drugs       Date:  1987-09       Impact factor: 9.546

Review 4.  Subacute sclerosing panencephalitis.

Authors:  R K Garg
Journal:  Postgrad Med J       Date:  2002-02       Impact factor: 2.401

5.  Combinations of isoprinosine and 3'-azido-3'-deoxythymidine in lymphocytes infected with human immunodeficiency virus type 1.

Authors:  R F Schinazi; D L Cannon; B H Arnold; D Martino-Saltzman
Journal:  Antimicrob Agents Chemother       Date:  1988-12       Impact factor: 5.191

Review 6.  Drug interactions with antiviral drugs.

Authors:  A M Taburet; E Singlas
Journal:  Clin Pharmacokinet       Date:  1996-05       Impact factor: 6.447

7.  Clinical and immunological assessment in HIV+ subjects receiving inosine-pranobex. A randomised, multicentric study.

Authors:  C De Simone; F Albertini; M Almaviva; G Angarano; F Chiodo; P Costigliola; S Delia; A Ferlini; F Gritti; G Mazzarello
Journal:  Med Oncol Tumor Pharmacother       Date:  1989

8.  Inhibition of Pneumocystis carinii dihydropteroate synthetase by para-acetamidobenzoic acid: possible mechanism of action of isoprinosine in human immunodeficiency virus infection.

Authors:  J A Kovacs; F Powell; D Voeller; C J Allegra
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

9.  The novel inosine analogue, INO-2002, protects against diabetes development in multiple low-dose streptozotocin and non-obese diabetic mouse models of type I diabetes.

Authors:  Jon G Mabley; Pal Pacher; Kanneganti G K Murthy; William Williams; Garry J Southan; Andrew L Salzman; Csaba Szabo
Journal:  J Endocrinol       Date:  2008-06-18       Impact factor: 4.286

10.  Inosine protects against the development of diabetes in multiple-low-dose streptozotocin and nonobese diabetic mouse models of type 1 diabetes.

Authors:  Jon G Mabley; Alex Rabinovitch; Wilma Suarez-Pinzon; György Haskó; Pál Pacher; Robert Power; Gary Southan; Andrew Salzman; Csaba Szabó
Journal:  Mol Med       Date:  2003 Mar-Apr       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.